You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

90 Results
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Palliative
Jan 2024
Regimen
Regimen
Regimen
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
Jan 2024
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
New Drug Funding Program
    Cabazitaxel - Metastatic Castration Resistant Prostate Cancer
ODB - General Benefit
    prednisone
Nov 2024
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI)
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
ODB - General Benefit
    temozolomide
Jun 2024
Regimen
Cancer Type:
Gynecologic, 
Cervix, 
Endometrial, 
Ovary, 
Vulva
Intent: Adjuvant, Palliative
Nov 2024
Regimen
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Curative, Palliative
Oct 2024

Pages